Dae Seog Heo

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers

Tae Min Kim, Hee-Jin Jang, Chan-Young Ock, 2017, Nature Communications.

Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma

Dong Soo Lee, Tae Min Kim, June-Key Chung, 2013, Cancer.

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

Young Tae Kim, Doo Hyun Chung, Tae-You Kim, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

Tae Min Kim, Doo Hyun Chung, Heounjeong Go, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors

Jin Mo Goo, Chang Min Park, Tae Min Kim, 2017, PloS one.

Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies

Tae-You Kim, Jae-Yong Chung, Noe Kyeong Kim, 2004, Clinical Cancer Research.

Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters

Young Il Yeom, D. Heo, Y. Yeom, 2006, Cancer biology & therapy.

Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma

Andreas Engert, Arnold S. Freedman, Martin J. S. Dyer, 2014, British journal of haematology.

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer

Tae Min Kim, Miso Kim, Young Sik Park, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Tae Min Kim, Doo Hyun Chung, Dong-Wan Kim, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Yan Sun, Lucio Crino, Xiuyu Julie Cong, 2012, The Lancet. Oncology.